Esperion to Participate in Upcoming Investor Conferences
May 10 2019 - 8:00AM
Esperion (NASDAQ:ESPR) today announced that the company will
participate in analyst-led fireside chats with investors at the
following conferences:
- Bank of America Merrill Lynch Healthcare Conference
2019 in Las Vegas on Tuesday, May 14, 2019 at 6:55 p.m.
E.T.
- UBS Global Healthcare Conference in New York
on Monday, May 20, 2019 at 9:30 a.m. E.T.
A live audio webcast of the UBS event can be accessed on the
investor relations section of the Esperion website
at www.esperion.com. Replay of the webcast will be archived on
the Company's website for 90 days following the event.
Bempedoic Acid
Bempedoic acid is our lead, non-statin, complementary, orally
available, once-daily, LDL-C lowering therapy. With a targeted
mechanism of action, bempedoic acid is a first-in-class, ATP
Citrate Lyase (ACL) inhibitor that reduces cholesterol biosynthesis
and lowers LDL-C by up-regulating the LDL receptor. Similar to
statins, bempedoic acid also reduces high sensitivity C-reactive
protein (hsCRP), a key marker of inflammation associated with
cardiovascular disease. Completed Phase 3 studies conducted in more
than 4,000 patients, with over 2,600 patients treated with
bempedoic acid, have produced an additional 18 percent LDL-C
lowering when used with moderate- and high-intensity statins and 28
percent LDL-C lowering when used with no background statin.
Bempedoic Acid / Ezetimibe Combination
Tablet
Through the complementary mechanisms of action of inhibition of
cholesterol synthesis (bempedoic acid) and inhibition of
cholesterol absorption (ezetimibe), the bempedoic acid / ezetimibe
combination tablet is a non-statin, orally available, once-daily,
LDL-C lowering therapy. Inhibition of ATP Citrate Lyase (ACL) by
bempedoic acid reduces cholesterol biosynthesis and lowers LDL-C by
up-regulating the LDL receptor. Inhibition of Niemann-Pick C1-Like
1 (NPC1L1) by ezetimibe results in reduced absorption of
cholesterol from the gastrointestinal tract, thereby reducing
delivery of cholesterol to the liver, which in turn upregulates the
LDL receptors. Phase 3 data demonstrated that this combination
results in a 29 percent LDL-C lowering when used with maximally
tolerated statins, a 44 percent LDL-C lowering when used with no
background statin (post-hoc analysis), and a 34 percent reduction
in hsCRP.
CLEAR Outcomes
The effect of bempedoic acid on cardiovascular morbidity and
mortality has not yet been determined. Esperion initiated a global
cardiovascular outcomes trial (CVOT) to assess the effects of
bempedoic acid on the occurrence of major cardiovascular events in
patients with, or at high risk for, cardiovascular disease (CVD)
who are only able to tolerate less than the lowest approved daily
starting dose of a statin and considered "statin averse." The CVOT
— known as CLEAR Outcomes — is an event-driven, global, randomized,
double-blind, placebo-controlled study expected to enroll
approximately 12,600 patients with hypercholesterolemia and high
CVD risk at over 1,000 sites in approximately 30 countries.
Esperion's Commitment to Patients with
Hypercholesterolemia
High levels of LDL-C can lead to a build-up of fat and
cholesterol in and on artery walls (known as atherosclerosis),
potentially leading to cardiovascular events, including heart
attack or stroke. In the U.S., 96 million people, or more than 37
percent of the adult population have elevated LDL-C. There are
approximately 18 million people in the U.S. with atherosclerotic
cardiovascular disease (ASCVD) who live with elevated levels of
LDL-C despite taking maximally tolerated lipid-modifying therapy —
including individuals considered statin averse — leaving them at
high risk for cardiovascular events. More than 50 percent of ASCVD
patients who are not able to reach their LDL-C goals with statins
alone need less than a 40 percent reduction to reach their LDL-C
threshold.Esperion's mission as the Lipid Management Company is to
deliver once-daily, oral therapies that complement existing oral
drugs to provide the additional LDL-C lowering that these patients
need.
The Lipid Management Company
Esperion is the Lipid Management Company passionately committed
to developing and commercializing complementary, cost-effective,
convenient, once-daily, oral therapies for the treatment of
patients with elevated LDL-C. Through scientific and clinical
excellence, and a deep understanding of cholesterol biology, the
experienced Lipid Management Team at Esperion is committed to
developing new LDL-C lowering therapies that will make a
substantial impact on reducing global cardiovascular disease; the
leading cause of death around the world. Bempedoic acid and the
bempedoic acid / ezetimibe combination tablet are targeted
therapies that have been shown to significantly lower elevated
LDL-C levels in patients with hypercholesterolemia, including
patients inadequately treated with current lipid-modifying
therapies. For more information, please
visit www.esperion.com and follow us on Twitter
at https://twitter.com/EsperionInc.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding the regulatory
approval pathway for bempedoic acid and the bempedoic acid /
ezetimibe combination tablet and the therapeutic potential of,
clinical development plan for, bempedoic acid and the bempedoic
acid / ezetimibe combination tablet, including Esperion's timing,
designs, plans and announcement of results regarding its CLEAR
Outcomes study and other ongoing clinical studies for bempedoic
acid and the bempedoic acid / ezetimibe combination tablet, timing
for the review and approval of the NDAs and the MAAs and Esperion's
expectations for the market for therapies to lower LDL-C, including
the market adoption of bempedoic acid and the bempedoic acid /
ezetimibe combination tablet, if approved, Esperion’s cash position
and financial outlook, and the expected upcoming milestones
described in this press release. Any express or implied statements
contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements.
Forward-looking statements involve risks and uncertainties that
could cause Esperion's actual results to differ significantly from
those projected, including, without limitation, delays or failures
in Esperion’s studies, that positive results from a clinical study
of bempedoic acid may not be sufficient for FDA or EMA approval or
necessarily be predictive of the results of future or ongoing
clinical studies, that notwithstanding the completion of Esperion’s
Phase 3 clinical development program for LDL-C lowering, the FDA or
EMA may require additional development in connection with seeking
regulatory approval, that existing cash resources may be used more
quickly than anticipated, and the risks detailed in Esperion's
filings with the Securities and Exchange Commission. Esperion
disclaims any obligation or undertaking to update or revise any
forward-looking statements contained in this press release, other
than to the extent required by law.
Investor Contact: Alex Schwartz Esperion
734-249-3386 aschwartz@esperion.com
Media Contact: Elliot Fox W2O Group 212-257-6724
efox@purecommunications.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Apr 2024 to May 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From May 2023 to May 2024